Answers - Legal

The Securities and Exchange Commission, also referred to as the SEC, was created bac

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

k in 1934 by section 4 of the Securities Exchange Act of 1934. It was created to reg

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

late the securities industry, protect investors from fraud, as well as to enforce fe

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

eral securities laws. Some of the federal securities laws that are enforced by the S

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

C include: the Securities Act of 1933, the Trust Indenture Act of 1939, the Investme

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

t Company Act of 1940, the Investment Advisers Act of 1940 and the Sarbanes-Oxley Ac

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

t of 2002.

The Securities and Exchange Commission requires public companies in the

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

nited States to periodically file a variety of financial reports with the SEC. In ad

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ition to filing these reports with the SEC public companies must also make these fin

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ncial reports available to the public. Investors can then use these financial report

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

to determine the soundness of potential investments in the company. Some of the mos

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

t common SEC filing types include: F-1, 4, S-1, POS AM, 13D, 144, 20-F, ARS, 6-K, 10

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

Q, 10-K and 8-K. These reports cover proposed sales of securities, transfers of owne

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ship and management, quarterly reports and annual reports.

If you are interested in

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

learning more about the SEC and the laws that it enforces then you should read throu

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

h the following United States Securities Laws: the Securities Act of 1933, the Secur

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ities Exchange Act of 1934, the Public Utility Holding Company Act of 1935, the Trus

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

Indenture Act of 1939, the Investment Company Act of 1940, the Investment Advisers

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ct of 1940 and the Securities Investor Protection Act of 1970. These acts can be req

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ested from the SEC or from the federal government printing office in Washington, D.C

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answers.org.ua/article/131259/answers-What-is-the-Securities-and-Exchange-Commission.html">What is the Securities and Exchange Commission?</a>

BB link (for phorums):
[url=http://www.answers.org.ua/article/131259/answers-What-is-the-Securities-and-Exchange-Commission.html]What is the Securities and Exchange Commission?[/url]

During the last few weeks of my role in the supermarket one of the managers that I wasn't familiar with started picking on me. At first I thought he was picking on me because I came from a European background, later I found out he treated majority of the junior staff this way and I finally understood that he was doing it just because he could.

I hope not a single SEO webmaster will read this issue. That's because, in a way, it's outrageous! I didn't do anything to deserve so many top 10 positions. Does this bring me MORE sales? Read the full story to find the answer...

Tags

Links

Answers - What is the Securities and Exchange Commission?

Related Articles: